AES 2022

December 02-06, 2022
Nashville, TN

American Epilepsy Society 2022
Explore more Epilepsy congress materials
Material Type

Results(6)

Neuroscience
Seizure-Free Days as a Novel and Meaningful Outcome in Patients with Lennox-Gastaut Syndrome: Post Hoc Analysis of Patients Receiving Cannabidiol (CBD) in GWPCARE3 and GWPCARE4
Author(s): Stephane Auvin MD, Pediatric Neurology Department & INSERM U1141, et al.
Seizure Outcomes With Cannabidiol (CBD) in Pediatric Versus Adult Patients With Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS): Subgroup Analysis of BECOME, a Caregiver Survey
Author(s): Timothy B. Saurer Ph.D., Jazz Pharmaceuticals, et al.
REST-LGS TOOL: Real World Use to Screen for LGS and Improve Access to Care
Author(s): Steven M. Wolf, MD, Boston Children’s Hospital Physicians, et al.
Nonseizure Outcomes With Cannabidiol (CBD) in Pediatric Versus Adult Patients With Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS): Subgroup Analysis of BECOME, a Caregiver Survey
Author(s): Tracy Dixon-Salazar Ph.D., LGS Foundation, et al.
Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) for Seizures Associated with Tuberous Sclerosis Complex (TSC): 3-Year Results From GWPCARE6 Open-Label Extension (OLE)
Author(s): Elizabeth Thiele MD, PhD, Massachusetts General Hospital, et al.
Dravet Syndrome Natural History: Placebo-Treated Patients in Clinical Trials
Author(s): Rima Nabbout MD, Reference Centre for Rare Epilepsies, Department of Pediatric Neurology, Necker Enfants Malades Hospital, Universite Paris Cité, Paris, France, et al.